Loading AI tools
Chemical compound From Wikipedia, the free encyclopedia
Suntinorexton (INN ; developmental code name TAK-861) is an experimental orexin receptor agonist.[1][2] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.[3] Suntinorexton has superseded danavorexton (TAK-925) and firazorexton (TAK-994) as a clinical drug candidate owing to toxicity of these agents.[1] The drug has reached phase 3 clinical trials as of 2024.[1][4] It is orally active and centrally penetrant.[1]
Clinical data | |
---|---|
Routes of administration | By mouth[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C23H28F2N2O4S |
Molar mass | 466.54 g·mol−1 |
3D model (JSmol) | |
| |
|
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.